Lupin is set to become first Indian company to fully integrate Honeywell’s Solstice Air in its respiratory inhalers at scale, redefining respiratory care with near-zero global warming potential propellants
Global pharma major Lupin Limited announced its plan to use Honeywell’s Solstice Air propellant to transform respiratory care through the development of next-generation inhalers. Designed for patients with asthma and chronic obstructive pulmonary disease (COPD), Honeywell Solstice Air has the potential to prevent the release of high global warming potential (GWP) molecules, marking a major step forward in helping to reduce carbon emissions.
Health Technology Insights: TruBridge Enhances Community Healthcare with Microsoft Collaboration
Lupin intends to become the first pharmaceutical company in India to use Honeywell’s Solstice Air product at scale as a next-generation propellant in pressurized metered-dose inhalers (pMDIs). Solstice Air offers an alternative to traditional hydrofluorocarbon (HFC)-based propellants, helping to reduce greenhouse gas emissions by up to 99.9%.1 By investigating the use of this innovative, non-flammable propellant in its pMDIs, Lupin is taking a significant step toward minimizing the environmental impact of respiratory solutions while providing effective treatment options for patients with asthma and COPD.
Health Technology Insights: Prolucent Appoints Staci Roberts as Chief Executive Officer
“Lupin’s partnership with Honeywell underscores our commitment to delivering high-quality medicines while working towards a healthier, more sustainable future for our patients and communities worldwide. By integrating Solstice Air in our products, we are not only enhancing patient care, but we are also significantly reducing environmental impact,” said Vinita Gupta, CEO, Lupin.
“Solstice Air can play a critical role in ensuring that Lupin life-saving devices provide safe and effective treatment options that also leverage the latest advancements in technology to reduce harmful greenhouse gas emissions,” said Jeff Dormo, a president in Honeywell’s Energy and Sustainability Solutions business. “By continuing to research and develop advanced technologies for reducing carbon, Honeywell is dedicated to driving innovation that enhances the efficacy of health solutions while pioneering emissions reducing practices that support industry advancements.”
Health Technology Insights: FDA Grants Interchangeable Designation to Fresenius Kabi’s biosimilar Otulfi
To participate in our interviews, please write to our HealthTech Media Room at sudipto@intentamplify.com
Source – PR Newswire
